Is paromomycin (antibiotic) widely used in the Philippines for treating infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Paromomycin Usage in the Philippines

Paromomycin is not widely used in the Philippines, as it is primarily utilized in specialized applications for leishmaniasis and intestinal amebiasis rather than as a common antibiotic for general infections. 1, 2

Current Applications of Paromomycin

  • Paromomycin is FDA-approved specifically for intestinal amebiasis and as adjunctive therapy in hepatic coma, not for general bacterial infections 2
  • In leishmaniasis treatment, paromomycin is used as a topical preparation (15% paromomycin with other ingredients) for cutaneous leishmaniasis, primarily in specialized settings 1
  • For intestinal amebiasis, paromomycin serves as a luminal agent (500 mg three times daily for 7 days) following treatment with metronidazole 3

Limitations to Widespread Use

  • Paromomycin has been largely replaced by other antibiotics for general infections and is now considered "out of use as an antibiotic" in most clinical settings 4
  • The drug's primary current applications are for specific parasitic infections rather than bacterial infections 2, 4
  • In leishmaniasis treatment, paromomycin formulations often require compounding pharmacies to prepare specialized topical preparations, limiting widespread availability 1

Regional Considerations

  • In Southeast Asia, paromomycin was licensed in 2007 specifically for visceral leishmaniasis treatment in India, not for general antibiotic use 4
  • The distribution of paromomycin for leishmaniasis is recommended to be "well regulated and preferably restricted to the public sector" rather than widely available 4
  • For cutaneous leishmaniasis, paromomycin topical preparations have shown approximately 80% cure rates in clinical trials in Panama and Tunisia, but these remain specialized applications 5

Clinical Implications

  • When treating intestinal amebiasis in the Philippines, physicians should be aware that paromomycin is available as a luminal agent but is not commonly stocked in many pharmacies 3, 2
  • For bacterial infections, other more widely available antibiotics are preferred over paromomycin 1, 4
  • The specialized nature of paromomycin's applications (parasitic rather than bacterial infections) contributes to its limited use in general practice 2, 4

Common Pitfalls

  • Assuming paromomycin is readily available for prescription in the Philippines when it may require special ordering or may not be stocked in many pharmacies 2, 4
  • Considering paromomycin as a first-line agent for bacterial infections when it is primarily indicated for specific parasitic conditions 2, 4
  • Failing to recognize that while paromomycin shows promise in research settings for conditions like leishmaniasis, its clinical use remains specialized rather than widespread 4, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Intestinal Amoebiasis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Paromomycin.

Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009

Research

Topical paromomycin for New World cutaneous leishmaniasis.

PLoS neglected tropical diseases, 2019

Research

Paromomycin in the treatment of leishmaniasis.

Expert opinion on investigational drugs, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.